Diabetes Monit 2002;3(4):306-314.
제2형 당뇨병에서 Rosiglitazone과 Sulfonylurea 병합요법의 혈당 개선 효과의 후향적 연구
김군순, 나소영, 이효진, 홍우정, 조영석, 구본정, 송민호, 노흥규, 김영건
A Retrospective Study of Rosiglitazone Combination Therapy with Sulfonylurea in Improvement of Glycaemic Control with Type 2 Diabetic Patients
Koon Soon Kim, So Young Rha, Hyo Jin Lee, Woo Jeong Hong, Young Suk Jo, Bon Jeong Ku, Min Ho Shong, Heung Kyu Ro, Young Kun Kim
Abstract
Background
This study was designed to evaluate the blood glucose lowering effects of rosiglitazone combination therapy with sulfonylurea in poor glycaemic controlled, type 2 diabetes. The factors affecting the response to rosiglitazone combination therapy with sulfonylurea were also evaluated on the basis of the degree of glycaemic control. Method: The 52 patients with type 2 diabetes who participated in this retrospective study had poor glycaemic control in spite of proper diet (30 kcal/kg), exercise (1hour walking/day) or antidiabetic medications; FBS ≥140 mg/dL, PP2 ≥ 200 mg/dL or HbA1C ≥8%. They received rosiglitazone 4 mg once daily with sulfonylurea for 6 months or more. We evaluated the change of hemoglobin A1c (HbA1C), fasting blood glucose, and post prandial blood sugar level, relative to baseline levels. The factors affecting response of rosiglitazone combination therapy with sulfonylurea were defined as body mass index (BMI), duration of diabetes, c-peptide and age. The patients with a decrement of HbA1C level more than 1% were defined as responders. Results: Rosiglitazone combination therapy with sulfonylurea significantly improved glycaemic control. The mean HbA1C reduction from the baseline was 1.5%. The factors (BMI, duration of diabetes, c-peptide and age) between non-responder and responder in HbA1c reduction were not statistically different. Conclusion: Rosiglitazone (4 mg/day) combination therapy with sulfonylurea resulted in a significant improvement in glycaemic control with type 2 diabetic patients who had poor glycaemic control.
Key Words: Type 2 Diabetes, Glycaemic control, Rosiglitazone combination therapy with sulfonylurea


Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2021 by Korean Diabetes Association. All rights reserved.

Developed in M2PI

Close layer